For the last 20 years, DePuy Spine's innovative and clinically proven surgical devices and instruments have helped patients suffering from spinal disorders reduce their pain or improve their mobility. DePuy Spine is a total spine company that operates across the spectrum of spinal disorders from degenerative disease to complex and aging conditions. We're proud to offer one of the strongest and broadest portfolios in spinal surgery in the world.

1993 - DePuy enters into spinal implant market by forming a joint venture with Biedermann Motech, a German manufacturer in the spinal market. The new company is named DePuy Motech, Inc.

1998 - DePuy Motech, Inc. acquires AcroMed Corp., the developer of the first pedicle screw fixation system, and changes its name to DePuy AcroMed, Inc.

1998 - Johnson & Johnson acquires DePuy AcroMed, Inc.

2003 - To signify a pivotal point in the history of its spine division and reflect its mission and growing position in the DePuy franchise, the DePuy AcroMed division of DePuy, Inc., is renamed DePuy Spine, Inc.

2004 - The CHARITÉ® Artificial Disc is the first artificial disc to be approved by the U.S. Food & Drug Administration (FDA) as a surgical treatment for patients suffering with single-level degenerative disc disease (DDD) at levels L4–5 or L5–S1 in the spine

2004 - DePuy Spine introduces the EXPEDIUM™ Spine System, designed to offer specific solutions for the unique needs of individuals with spinal injuries ranging from scoliosis to degenerative disc disease

2007 - DePuy Spine introduces eight new products to the market, including AEGIS™, the company’s first anterior plate system designed to treat degenerative conditions of the lumbar spine

The CHARITÉ® Artificial Disc is indicated for spinal arthroplasty in skeletally mature patients with degenerative disc disease (DDD) at one level from L4-S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies. These DDD patients should have no more than 3mm of spondylolisthesis at the involved level. Patients receiving the CHARITÉ Artificial Disc should have failed at least six months of conservative treatment prior to implantation of the CHARITÉ Artificial Disc.